Accuracy of budget impact estimations and impact on patient access:a hepatitis C case study
Background High budget impact (BI) estimates of new drugs limit access to patients due to concerns regarding affordability and displacement effects. The accuracy and methodological quality of BI analyses are often low, potentially mis-informing reimbursement decision making. Using hepatitis C as a case study, we aim to quantify the accuracy of the BI predictions used in Dutch reimbursement decision-making and to characterize the influence of market-dynamics on actual BI. Methods We selected hepatitis C direct-acting antivirals ( DAAs) that were introduced in the Netherlands between January 201... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | Geenen , J W , Boersmaz , C , Klungel , O H & Hovels , A M 2019 , ' Accuracy of budget impact estimations and impact on patient access : a hepatitis C case study ' , European Journal of Health Economics , vol. 20 , no. 6 , pp. 857-867 . https://doi.org/10.1007/s10198-019-01048-z |
Schlagwörter: | Hepatitis C / Budget impact / Budget impact accuracy / Direct-acting antivirals / Affordability / Pharmaceuticals / VIRUS-INFECTION / ECONOMIC-EVALUATION / REIMBURSEMENT / EPIDEMIOLOGY / CARE / NETHERLANDS / MEDICINES / COUNTRIES / EUROPE / DRUGS |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28780076 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/d2b02ce2-33c2-46bf-b988-274d21481ee3 |